Management of Hyperkalemia: Stepwise Approach
The management of hyperkalemia follows a three-tiered approach: (1) immediate cardiac membrane stabilization with IV calcium for severe cases with ECG changes, (2) rapid intracellular potassium shift using insulin/glucose and/or beta-agonists, and (3) total body potassium removal through diuretics, newer potassium binders (SZC or patiromer), or dialysis—while critically avoiding discontinuation of RAASi therapy in patients with heart failure or chronic kidney disease. 1, 2
Acute Hyperkalemia Management
Step 1: Cardiac Membrane Stabilization (Immediate - Within 1-3 Minutes)
- Administer IV calcium gluconate if potassium >6.0 mEq/L OR any ECG changes are present 2
- Acts within 1-3 minutes to reduce cardiac membrane excitability
- Critical caveat: Absence of ECG changes does NOT exclude the need for urgent treatment—ECG findings are highly variable and not as sensitive as laboratory values for predicting complications 2
- If no effect within 5-10 minutes, give a second dose 2
- This does NOT lower serum potassium; it only protects the heart
Step 2: Intracellular Shift (Onset 30 Minutes)
- IV insulin 10 units with 50 mL of 50% glucose (D50)
- PLUS inhaled albuterol 10-20 mg by nebulizer
- Can be repeated as needed until definitive removal strategies are implemented
Sodium bicarbonate has fallen out of favor:
- Only consider if concurrent metabolic acidosis is present 2
- Poor efficacy when used alone 3
- Risk of sodium overload 1
Step 3: Total Body Potassium Removal
For Acute Management:
Newer potassium binders are preferred 1, 2:
Sodium zirconium cyclosilicate (SZC): 10g three times daily for up to 48 hours
Patiromer: 8.4g once daily (can titrate to 25.2g)
Dialysis: Reserved for severe, refractory cases or when other measures fail 1, 2
Chronic Hyperkalemia Management
Initial Approach: Correct Reversible Factors First 1
- Review and discontinue unnecessary medications causing hyperkalemia
- Optimize diuretic therapy (loop or thiazide diuretics to increase urinary potassium excretion) 2
- Correct metabolic acidosis if present
- Address constipation
- Dietary modification: Focus on reducing non-plant sources of potassium rather than blanket restriction of all high-potassium foods 1, 4
Long-Term Potassium Control
If no reversible factors exist, initiate preventive treatment 1:
Newer potassium binders for maintenance:
Avoid sodium polystyrene sulfonate (SPS) for chronic use due to variable efficacy and safety concerns 2
Critical Management Principle: Preserve RAASi Therapy
Down-titration or discontinuation of RAASi should NOT be the default management option for hyperkalemia 1, 2:
- Only 51.5% of eligible patients with CKD/HF receive RAASi despite clear mortality benefits 5
- RAASi improve outcomes in heart failure and proteinuric kidney disease 4
- Use newer potassium binders to enable RAASi continuation and optimization 1, 2
RAASi Reinitiation Guidelines 2:
- Mild hyperkalemia (5.0-5.5 mEq/L): RAASi usually not stopped
- Moderate (5.6-5.9) or severe (>5.9): Reinitiate once potassium <5.0 mEq/L and contributing factors controlled
- Reintroduce agents one at a time with close monitoring
Monitoring Strategy
- Check potassium 7-10 days after starting or increasing RAASi dose 2
- High-risk patients (CKD, diabetes, HF, history of hyperkalemia): More frequent monitoring 2
- Chronic hyperkalemia patients: Every 3 months, or monthly if high-risk 6
Common Pitfalls to Avoid
- Relying solely on ECG: ECG changes are nonspecific and variable—treat based on potassium level and clinical context 2
- Prematurely stopping RAASi: This worsens long-term cardiovascular and renal outcomes 1, 4
- Using SPS chronically: Limited evidence, variable efficacy, and safety concerns 2
- Overly restrictive potassium diet: May conflict with heart-healthy diet; focus on non-plant sources 1, 4
- Inadequate monitoring after RAASi changes: 20% of patients experience recurrence 1